Oxsed Revenue and Competitors
Estimated Revenue & Valuation
- Oxsed's estimated annual revenue is currently $1.4M per year.
- Oxsed's estimated revenue per employee is $155,000
Employee Data
- Oxsed has 9 Employees.
- Oxsed grew their employee count by -18% last year.
Oxsed's People
Name | Title | Email/Phone |
---|
Oxsed Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Oxsed?
Oxsed has developed a rapid, accurate and scalable COVID-19 test that leverages patent-pending OxLAMP technology from the University of Oxford. In recent months, we have ramped up testing in the UK and have tested thousands of people daily, including passengers at Heathrow Airport. Last year, we were acquired by Prenetics in Hong Kong, a leader in digital health and diagnostics. We are committed to making COVID-19 testing accessible and affordable to everyone, and are well positioned to scale diagnostic and mass surveillance testing globally.
keywords:N/AN/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oxsed News
Tan said this was developed jointly by a Hong Kong-based company Prenetics Ltd and a leading research company, Oxsed, based at Oxford University...
The partnership follows Prenetics' acquisition of Oxsed, the spinout behind the University of Oxford's nasal swab rapid diagnostic test for...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1M | 12 | -14% | N/A |
#2 | $1M | 13 | N/A | N/A |
#3 | $1.7M | 19 | 12% | N/A |
#4 | $1.6M | 28 | 155% | N/A |
#5 | $7.7M | 38 | 6% | N/A |